{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:32:49Z","timestamp":1792125169382,"version":"4.4.0"},"reference-count":21,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Traditional conditioning regimens for patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) provide suboptimal outcomes, especially for older patients and those with comorbidities. We hypothesized that a fractionated myeloablative busulfan dose delivered over an extended period would reduce nonrelapse mortality (NRM) while retaining antileukemic effects. Here, we performed a phase 2 trial for adults with hematological malignancies receiving matched related or unrelated allo-HCT. Participants received busulfan 80\u00a0mg\/m2 as outpatients on days\u00a0\u221220 and\u00a0\u221213 before transplant. Fludarabine 40\u00a0mg\/m2 was administered on days\u00a0\u22126 to\u00a0\u22123, followed by busulfan dosed to achieve a target area under the curve of 20\u2009000 mol\/min for the whole course. The primary end point was day-100 NRM. Seventy-eight patients were included, with a median age of 61 years (range, 39-70 years), who received transplantation for acute leukemia (24%), myelodysplastic syndrome (27%), or myeloproliferative disease\/chronic myeloid leukemia (44%). HCT-specific comorbidity index (HCT-CI) was \u22653 in 34 (44%). With a median follow-up of 36.4\u00a0months (range, 2.9-51.5), the 100-day, 1-year, and 3-year NRM rates were 3.8%, 8%, and 9.3%, respectively, without a significant difference in age or HCT-CI score. The 1-year and 3-year relapse incidence was 10% and 18%, respectively. The 3-year overall survival was 80%, without a significant difference in age or HCT-CI score and was similar for patients aged &amp;gt;60 years and those aged &amp;lt;60 years as well as for those with HCT-CI \u22653 and HCT-CI\u00a0&amp;lt;3. Overall, a myeloablative fractionated busulfan regimen has low NRM without an increase in relapse rate, resulting in promising survival, even in older patients or in patients with comorbidities. This trial was registered at www.clinicaltrials.gov as #NCT02861417.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023010850","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T18:34:25Z","timestamp":1692815665000},"page":"6196-6205","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7592-2224","authenticated-orcid":false,"given":"Uday R.","family":"Popat","sequence":"first","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oren","family":"Pasvolsky","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"},{"name":"2Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel"},{"name":"3Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4534-2042","authenticated-orcid":false,"given":"Roland","family":"Bassett Jr.","sequence":"additional","affiliation":[{"name":"4Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8532-544X","authenticated-orcid":false,"given":"Rohtesh S.","family":"Mehta","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1669-0355","authenticated-orcid":false,"given":"Amanda","family":"Olson","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julianne","family":"Chen","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin M.","family":"Alousi","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7648-4377","authenticated-orcid":false,"given":"Gheath","family":"Al-Atrash","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4086-6453","authenticated-orcid":false,"given":"Qaiser","family":"Bashir","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1921-9152","authenticated-orcid":false,"given":"Alison M.","family":"Gulbis","sequence":"additional","affiliation":[{"name":"5Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitra M.","family":"Hosing","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5249-1177","authenticated-orcid":false,"given":"Jin S.","family":"Im","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partow","family":"Kebriaei","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issa","family":"Khouri","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Marin","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6034-8939","authenticated-orcid":false,"given":"Yago","family":"Nieto","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betul","family":"Oran","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Saini","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1322-9555","authenticated-orcid":false,"given":"Terri Lynn","family":"Shigle","sequence":"additional","affiliation":[{"name":"5Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer A.","family":"Srour","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy L.","family":"Ramdial","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katayoun","family":"Rezvani","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzaffar H.","family":"Qazilbash","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borje S.","family":"Andersson","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4314-5037","authenticated-orcid":false,"given":"Richard E.","family":"Champlin","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Shpall","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,10,13]]},"reference":[{"issue":"1","key":"2023102313410417600_bib1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bbmt.2013.10.018","article-title":"Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the Center for International Blood and Marrow Transplant Research","volume":"20","author":"Gupta","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2023102313410417600_bib2","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1200\/JCO.2009.25.4821","article-title":"Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome","volume":"28","author":"McClune","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2023102313410417600_bib3","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/cncr.33383","article-title":"Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"127","author":"Oran","year":"2021","journal-title":"Cancer"},{"issue":"8","key":"2023102313410417600_bib4","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"3","key":"2023102313410417600_bib5","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1182\/blood-2005-11-4503","article-title":"Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes","volume":"108","author":"Martino","year":"2006","journal-title":"Blood"},{"issue":"6","key":"2023102313410417600_bib6","doi-asserted-by":"crossref","first-page":"483.e1","DOI":"10.1016\/j.jtct.2021.02.031","article-title":"Myeloablative versus reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes-long-term follow-up of the BMT CTN 0901 Clinical Trial","volume":"27","author":"Scott","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"2023102313410417600_bib7","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2023102313410417600_bib8","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/bmt.2016.322","article-title":"Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML\/MDS patients","volume":"52","author":"Andersson","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2023102313410417600_bib9","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.bbmt.2020.03.020","article-title":"Optimizing the conditioning regimen for hematopoietic cell transplant in myelofibrosis: long-term results of a prospective phase II clinical trial","volume":"26","author":"Popat","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2023102313410417600_bib10","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1016\/S2352-3026(18)30156-X","article-title":"Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial","volume":"5","author":"Popat","year":"2018","journal-title":"Lancet Haematol"},{"issue":"11","key":"2023102313410417600_bib11","doi-asserted-by":"crossref","first-page":"913.e1","DOI":"10.1016\/j.jtct.2021.07.021","article-title":"Myeloablative fractionated busulfan with fludarabine in older patients: long term disease-specific outcomes of a prospective phase II clinical trial","volume":"27","author":"Mehta","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"2023102313410417600_bib12","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1038\/s41409-021-01274-1","article-title":"Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality","volume":"56","author":"Ramdial","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2023102313410417600_bib13","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.3324\/haematol.2022.280778","article-title":"A\u00a0myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA-matched and haploidentical transplantation: results of a phase II study","volume":"107","author":"Popat","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"2023102313410417600_bib14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"2023102313410417600_bib15","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the disease risk index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2023102313410417600_bib16","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/j.bbmt.2020.09.013","article-title":"Barriers to hematopoietic cell transplantation for adults in the United States: a systematic review with a focus on age","volume":"26","author":"Flannelly","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2023102313410417600_bib17","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1182\/blood-2003-10-3561","article-title":"Randomized comparison of double induction and timed-sequential induction to a \u201c3\u00a0+ 7\u201d induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study","volume":"104","author":"Castaigne","year":"2004","journal-title":"Blood"},{"issue":"7","key":"2023102313410417600_bib18","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.leukres.2009.11.007","article-title":"Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia","volume":"34","author":"Karp","year":"2010","journal-title":"Leuk Res"},{"issue":"3","key":"2023102313410417600_bib19","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2005-10-4165","article-title":"Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation","volume":"108","author":"Schmid","year":"2006","journal-title":"Blood"},{"issue":"9","key":"2023102313410417600_bib20","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3324\/haematol.2015.125849","article-title":"Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine\/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia","volume":"100","author":"Zeidner","year":"2015","journal-title":"Haematologica"},{"issue":"35","key":"2023102313410417600_bib21","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1200\/JCO.2015.62.7273","article-title":"Phase II study of allogeneic transplantation for older patients with acute myeloid leukemia in first complete remission using a reduced-intensity conditioning regimen: results from Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)\/Blood and Marrow Transplant Clinical Trial Network 0502","volume":"33","author":"Devine","year":"2015","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/20\/6196\/2085312\/blooda_adv-2023-010850-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/20\/6196\/2085312\/blooda_adv-2023-010850-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T13:41:46Z","timestamp":1698068506000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/20\/6196\/497571\/Myeloablative-fractionated-busulfan-for-allogeneic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":21,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2023,10,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010850","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,13]]}}}